This paper is only available as a PDF. To read, Please Download here.
Abstract
Thirty-six patients undergoing curative resection for colorectal cancer were studied
to determine the effect of the tumor on lymphocytes circulating through it. In the
venous blood draining the tumor, there was an increased percentage of natural killer
(NK) cells (p = 0.001), no difference in overall NK cell function, and decreased T-lymphocyte
activation (p = 0.035) and proliferation (p = 0.002) compared with the lymphocytes
in the arterial blood supplying the tumor. There were no significant differences in
the control group of 16 patients. Local effects of colorectal cancer may include the
ability to down-regulate T and NK cell function while increasing the number of NK
cells. Means of enhancing antitumor activity therapeutically in an adjuvant setting,
possibly through the portal vein during surgery, need to be considered, especially
in the light of the immunosuppressive effects of surgery.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The influence of surgical operations on components of the human immune system.Br J Surg. 1985; 72: 771-776
- Need for immunologic stimulators during immunosuppression produced by major cancer surgery.Ann Surg. 1985; 202: 9-20
- Circulating cancer cells during excision of carcinomas of the rectum and colon with high ligation of the inferior mesenteric vein.Surg Gynecol Obstet. 1965; 120: 1266-1270
- Carcinoma of the colon and rectum: circulating malignant cells and five-year survival.Cancer. 1973; 31: 226-236
- OPCS Monitor. Office of Population and Census Surveys, LondonMarch 1986
- Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.N Engl J Med. 1985; 313: 1485-1492
- A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.N Engl J Med. 1987; 316: 889-897
- Adoptive immunotherapy of human cancer using low-dose recombinant interleukin-2 and lymphokine-activated killer cells.Cancer Res. 1988; 48: 5007-5010
- Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma.N Engl J Med. 1988; 319: 1676-1680
- Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.Lancet. 1989; i: 577-580
- Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.N Engl J Med. 1990; 322: 352-358
- Natural killer cells: their role in defenses against disease.Science. 1981; 214: 24-30
- Natural killer cells and their possible roles in host resistance against tumors.Transplant Proc. 1984; 16: 476-478
- Surgery of the anus, rectum and colon.in: 5th ed. Balliere Tindall, Eastborne1984: 485
- The portal vein and colorectal cancer.Br J Surg. 1988; 75: 402-403
- Depressed natural killer cell activity in blood-draining digestive tract tumours in man.Br J Cancer. 1984; 49 ([Abstract]): 396
- Host anti-tumour defenses are not directly inhibited by lymphocyte circulation through the primary tumour.Br J Surg. 1989; 76 ([Abstract]): 631
- Local immune mechanisms in inflammatory bowel disease and colorectal carcinoma.Gastroenterology. 1986; 90: 12-19
- Characterization of lymphocytes found in colon cancer.Gastroenterology. 1987; 92 ([Abstract]): 1380
- Human mucosal cytotoxic: effector cells.Gastroenterology. 1987; 92: 1951-1957
- Immunology of tumor-infiltrating lymphocytes.Ann Surg. 1985; 201: 158-163
- Extravascular natural cytotoxicity in man: anti-K562 activity of lymph node and tumour-infiltrating lymphocytes.Br J Cancer. 1981; 27: 265-272
- Natural killer cells in human solid tumors.Cancer Metastasis Rev. 1983; 2: 337-350
- Impaired local natural killer cell activity in human colorectal carcinomas.Cancer Immunol Immunother. 1989; 28: 301-304
- In situ subpopulations of lymphocytes in human colorectal carcinomas.Invasion Metastasis. 1984; 4: 60-66
- Specific and nonspecific lymphocyte cytotoxicity in colon carcinoma.Br J Cancer. 1981; 44: 846-855
- The nature of the natural killer (NK) cell of human intestinal mucosa and mesenteric lymph node.Clin Exp Immunol. 1985; 61: 160-168
- Systemic and in situ natural killer cell activity in tumor-bearing mice and patients with cancer.in: Herberman RB Natural cell-mediated immunity against tumors. Academic Press, New York1980: 1047-1062
- Modulation of natural killer cell cytotoxicity by tumours of the gastrointestinal tract.Br J Surg. 1983; 70 ([Abstract]): 695
- Natural killer cell (NK) function: is the colon an immunosuppressive organ?.Br J Surg. 1989; 76 ([Abstract]): 632
- Depression of human natural killer lymphocyte activity after exposure to peripheral and tumour draining venous plasma of cancer patients.Br J Surg. 1984; 71 ([Abstract]): 911
- Role of natural killer cells in the destruction of circulating tumor emboli.J Natl Cancer Inst. 1980; 65: 801-809
- Role of NK cells in the control of metastatic spread and growth of tumor cells in mice.Int J Cancer. 1982; 30: 107-112
- In vivo reduction of NK activity with anti-NK1 serum: direct evaluation of NK cells in tumor clearance.Int J Cancer. 1982; 29: 203-207
- Abrogation of hematogenous metastases in a murine model by natural killer cells.Surgery. 1984; 96: 133-138
- Direct evidence for the role of LGL in the inhibition of experimental tumor metastases.J Immunol. 1985; 134: 2783-2789
- Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. I. The effect of malignant disease.Int J Cancer. 1976; 18: 593-604
- The prognostic significance of natural killer cell cytotoxicity in patients with colorectal cancer.Arch Surg. 1987; 122: 1264-1268
- Role of autologous lymphocyte cytotoxicity in colonic neoplasia.Gut. 1982; 23: 31-35
- Clinical and immunonological evaluation of twenty patients with advanced colorectal cancer treated with high-dose recombinant leukocyte interferon-alphaA (rIFNalphaA).Cancer Immunol Immunother. 1986; 21: 81-84
- Treatment of advanced colorectal carcinoma with 5-fluorouracil (5-FU) and alpha-interferon.in: European Conference on Clinical Oncology Conference Proceedings (satellite symposium: interferon alfa-2b). 1989: 10-11
- A phase I trial of recombinant gamma interferon in patients with cancer.Cancer Immunol Immunother. 1985; 20: 193-197
- Tumour necrosis factor in man: clinical and biological observations.Br J Cancer. 1987; 56: 803-808
- Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease.Cancer Immunol Immunother. 1989; 29: 144-150
- Clinical immunotherapy studies in the surgery branch of the U.S. National Cancer Institute: brief review.Cancer Treat Rev. 1989; 16: 115-122
- Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.N Engl J Med. 1987; 316: 898-905
- Continuous-infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies.Cancer Treat Rev. 1989; 16: 83-90
- Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations.J Natl Cancer Inst. 1989; 81: 602-611
- A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes.Science. 1986; 311: 1318-1321
- A progress report of a phase I study of interferon-gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2.Cancer Treat Rev. 1989; 16: 105-110
- A phase II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal cancer.Cancer Treat Rev. 1989; 16: 163-168
- Five-year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer.Br J Surg. 1987; 74: 569-572
- A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer.Br J Surg. 1985; 72: 359-363
- Intraportal chemotherapy in colorectal cancer as an adjuvant modality.World J Surg. 1987; 11: 542-548
Article info
Publication history
Accepted:
August 20,
1990
Footnotes
☆Supported by the North of England Cancer Research Campaign.
Identification
Copyright
© 1991 Published by Elsevier Inc.
